IMRX
USDImmuneering Corporation Class A Common Stock
Real-time Price
Price Chart
Key Metrics
Market Metrics
Open
$1.470
High
$1.490
Low
$1.430
Volume
0.00M
Company Fundamentals
Market Cap
52.5M
Industry
Biotechnology
Country
United States
Trading Stats
Avg Volume
0.21M
Exchange
NGM
Currency
USD
52-Week Range
Related News
Chardan Capital Maintains Buy on Immuneering, Maintains $13 Price Target
Chardan Capital analyst Geulah Livshits maintains Immuneering with a Buy and maintains $13 price target.
Immuneering Corporation Announces Grant of Inducement Award
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for
Needham Reiterates Buy on Immuneering, Maintains $12 Price Target
Needham analyst Ami Fadia reiterates Immuneering with a Buy and maintains $12 price target.
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer
Industry veteran brings extensive oncology drug development expertise and experience in clinical treatment of cancer patients Dr. Matushansky joins as Immuneering plans to present updated data from Phase 2a trial of
Related Stocks
Stay Updated
Set price alerts, get AI analysis updates and real-time market news.